Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov;34(6):e70009.
doi: 10.1002/rmv.70009.

Neuroinflammation in Post COVID-19 Sequelae: Neuroinvasion and Neuroimmune Crosstalk

Affiliations
Review

Neuroinflammation in Post COVID-19 Sequelae: Neuroinvasion and Neuroimmune Crosstalk

Roberta S Dos Reis et al. Rev Med Virol. 2024 Nov.

Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 triggered a swift global spread, leading to a devastating pandemic. Alarmingly, approximately one in four individuals diagnosed with coronavirus disease 2019 (COVID-19) experience varying degrees of cognitive impairment, raising concerns about a potential increase in neurological sequelae cases. Neuroinflammation seems to be the key pathophysiological hallmark linking mild respiratory COVID-19 to cognitive impairment, fatigue, and neurological sequelae in COVID-19 patients, highlighting the interaction between the nervous and immune systems following SARS-CoV-2 infection. Several hypotheses have been proposed to explain how the virus disrupts physiological pathways to trigger inflammation within the CNS, potentially leading to neuronal damage. These include neuroinvasion, systemic inflammation, disruption of the lung and gut-brain axes, and reactivation of latent viruses. This review explores the potential origins of neuroinflammation and the underlying neuroimmune cross-talk, highlighting important unanswered questions in the field. Addressing these fundamental issues could enhance our understanding of the virus's impact on the CNS and inform strategies to mitigate its detrimental effects.

PubMed Disclaimer

References

    1. K. D. Johnson, C. Harris, J. K. Cain, C. Hummer, H. Goyal, and A. Perisetti, “Pulmonary and Extra‐Pulmonary Clinical Manifestations of COVID‐19,” Frontiers of Medicine 7 (2020): 526, https://doi.org/10.3389/fmed.2020.00526.
    1. D. García‐Azorín, Á Sierra, J. Trigo, et al., “Frequency and Phenotype of Headache in Covid‐19: A Study of 2194 Patients,” Scientific Reports 11, no. 1 (2021): 14674, https://doi.org/10.1038/s41598‐021‐94220‐6.
    1. E. Meppiel, N. Peiffer‐Smadja, A. Maury, et al., “Neurologic Manifestations Associated With COVID‐19: A Multicentre Registry,” Clinical Microbiology and Infections 27, no. 3 (2021): 458–466, https://doi.org/10.1016/j.cmi.2020.11.005.
    1. M. Taquet, Q. Dercon, S. Luciano, J. R. Geddes, M. Husain, and P. J. Harrison, “Incidence, Co‐Occurrence, and Evolution of Long‐COVID Features: A 6‐Month Retrospective Cohort Study of 273,618 Survivors of COVID‐19,” PLoS Medicine 18, no. 9 (2021): e1003773, https://doi.org/10.1371/journal.pmed.1003773.
    1. L. Mao, H. Jin, M. Wang, et al., “Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China,” JAMA Neurology 77, no. 6 (April 2020): 683, https://doi.org/10.1001/jamaneurol.2020.1127.

LinkOut - more resources